Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
